Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

GSK bolsters respiratory portfolio with US$1.4b asthma treatment buy

Published 15/02/2024, 13:06
Updated 15/02/2024, 13:06
© Reuters. GSK bolsters respiratory portfolio with US$1.4b asthma treatment buy

Proactive Investors - GSK PLC (LON:GSK) has announced the US$1.4 billion acquisition of respiratory biopharmaceuticals firm Aiolos Bio.

FTSE 100-listed GSK said the takeover, which will see US$1 billion paid upfront followed by a further US$400 million in performance-linked payments, would offer it access to Aiolos’ long-acting anti-thymic stromal lymphopoietin (TSLP) treatment.

“Adding AIO-001, a potentially best-in-class medicine targeting the TSLP pathway, could expand the reach of our current respiratory biologics portfolio,” chief executive Tony Wood said.

The monoclonal antibody treatment is ready to enter phase two clinical development for the treatment of adult patients with asthma, GSK added.

It also has the potential for additional indications, such as chronic rhinosinusitis with nasal polyps.

“We believe that this transaction speaks to the high potential of our long-acting anti-TSLP monoclonal antibody,” Aiolos chief executive Khurem Farooq commented.

“By uniting with GSK [...] we’re confident that we can rapidly advance this therapy in the hopes of significantly reducing the treatment burden for patients.”

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.